Gapping up
In reaction to strong earnings/guidance:
- BNED +10.8%, DRI +9%, KR +8.9%, MU +5%, PDCO +2.1%
M&A news:
- MTCH +1.1% (acquired a 51% ownership stake in Hinge, the NYC-based relationship app; has the right to acquire all the remaining shares of Hinge within the next 12 months)
Argentina-exposed ADRs higher on MSCI reclassification to Emerging Markets status:
- TGS +20.6%, BFR +12.6%, EDN +11.6%, LOMA +11.3%, GGAL +11.1%, TEO +10.6%, BMA +9.4%, ARGT +8.8%, PAM +7.7%, YPF +6.6%, IRS +4.8%
Other news:
- CASI +38.2% (announces strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical Co., for the manufacturing of entecavir and cilostazol)
- MESO +7.4% (announces key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate)
- HPQ +2.6% (authorized an additional $4.0 billion for future repurchases of its outstanding shares of common stock)
- RYTM +2.2% (prices public offering of 5,732,000 shares of its common stock at a public offering price of $26.42 per share)
- WDC +2% (following MU results)
- LGF.A +2% (continued strength)
- THO +1.7% (announces $250 million share repurchase authorization)
- INCY +1.5% (announces 'positive' topline results from its ongoing pivotal Phase 2 REACH1 trial)
- FOXA +1.4% (extending today's move higher)
- AMD +0.9% (following MU results)
- SHPG +0.7% (announces FDA approval for label expansion of Cinryze for prevention of attacks in pediatric hereditary angioedema patients)
Analyst comments:
- LITE +4% (upgraded to Buy at Goldman)
- BDX +1.7% (upgraded to Overweight from Neutral at JP Morgan)
- GLW +1.4% (upgraded to Neutral from Sell at Goldman)
- VZ +1.3% (upgraded to Buy from Neutral at Goldman)
- CHTR +1.2% (upgraded to Buy from Neutral at Goldman)
![]()